Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in Michigan
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1RECRUITING
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
[68Ga]Ga-NNS309 · [177Lu]Lu-NNS309 — 29 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
64Cu-LNTH-1363S — 5 sites
- TRIALPHASE1RECRUITING
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PTM-101 — 8 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101 · Nab-paclitaxel · Gemcitabine — 93 sites
- TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 131 sites
- TRIALPHASE1 / PHASE2RECRUITING
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
ADC — 7 sites
- TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
MT-4561 — 6 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
XER-001 — 5 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
ASP546C — 21 sites
- TRIALPHASE2RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Capecitabine · Temozolomide — 448 sites
- TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
- TRIALPHASE1RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
LY3962673 · Cetuximab · Gemcitabine — 52 sites
- TRIALPHASE1RECRUITING
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
ASP5834 · panitumumab — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LCB84 · Anti-PD-1 monoclonal antibody — 8 sites
- TRIALPHASE1RECRUITING
A Study of MGC026 in Participants With Advanced Solid Tumors
MGC026 Dose Escalation · MGC026 Dose for Expansion — 12 sites
- TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
- TRIALPHASE1RECRUITING
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Capecitabine · Sacituzumab govetican — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
MRTX1719 — 25 sites
- TRIALPHASE2RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Zanidatamab — 28 sites
- TRIALNARECRUITING
The Vanguard Study: Testing a New Way to Screen for Cancer
Biospecimen Collection · Device Usage · Electronic Health Record Review — 44 sites
- TRIALPHASE2RECRUITING
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Relacorilant · Nab-paclitaxel · Gemcitabine — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Biospecimen Collection · Dual X-ray Absorptiometry · Tegavivint — 21 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
[64Cu]CM500 · [68Ga]CM500 · PET/MR — 3 sites
- TRIALPHASE1RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Azirkitug · Budigalimab · Bevacizumab — 48 sites
- TRIALPHASE1NOT_YET_RECRUITING
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
XNW28012 — 8 sites
- TRIALPHASE2RECRUITING
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Nab paclitaxel · Gemcitabine · TheraBionic P1 — 7 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
CP-383 — 13 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.